20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Beam Therapeutics Inc (BEAM) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 540 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, BEAM reported $140M in revenue and ($80M) in net income.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Interactive charts & full statements → Open the BEAM valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $156M | $140M | $64M | $378M | $61M | $52M | $0M | $0M | $0M | — |
| Gross Profit | $30M | $117M | ($304M) | $378M | ($251M) | ($180M) | ($103M) | ($55M) | ($34M) | $0M |
| Gross Margin % | 18.9% | 84.0% | -478.7% | 100.0% | -411.5% | -347.8% | -429812.5% | -303338.9% | — | — |
| Operating Income (EBIT) | ($378M) | ($384M) | ($416M) | ($176M) | ($338M) | ($392M) | ($133M) | ($75M) | ($46M) | ($9M) |
| Operating Margin % | -242.3% | -274.6% | -654.2% | -46.7% | -555.6% | -757.0% | -553166.7% | -417522.2% | — | — |
| Net Income | ($85M) | ($80M) | ($377M) | ($133M) | ($289M) | ($371M) | ($195M) | ($78M) | ($115M) | ($9M) |
| Net Margin % | -54.8% | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | -810800.0% | -435144.4% | — | — |
| EBITDA | ($60M) | ($30M) | ($355M) | ($102M) | ($272M) | ($230M) | ($128M) | ($72M) | ($45M) | ($9M) |
| Earnings Per Share (EPS) | $-0.86 | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-4.16 | $-1.53 | $-3.28 | $-0.67 |
| Shares Outstanding (M) | 104M | 99M | 82M | 77M | 70M | 64M | 47M | 51M | 35M | 13M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $32M | $114M | $10M | $8M | $7M | $30M | $14M |
| Gross Profit | $0M | $21M | $108M | ($100M) | ($93M) | ($91M) | ($71M) | ($80M) |
| Gross Margin % | 100.0% | 65.2% | 95.0% | -1031.9% | -1102.0% | -1222.8% | -237.4% | -560.6% |
| Operating Income (EBIT) | ($127M) | ($107M) | ($17M) | ($127M) | ($120M) | ($119M) | ($100M) | ($107M) |
| Operating Margin % | -25827.1% | -337.8% | -15.3% | -1307.6% | -1419.2% | -1596.9% | -332.7% | -746.4% |
| Net Income | ($123M) | ($94M) | $244M | ($113M) | ($102M) | ($109M) | ($90M) | ($97M) |
| Net Margin % | -25036.3% | -297.2% | 214.1% | -1162.4% | -1208.3% | -1462.8% | -300.5% | -677.5% |
| EBITDA | ($125M) | ($89M) | $261M | ($107M) | ($97M) | ($104M) | ($85M) | ($91M) |
| Earnings Per Share (EPS) | $-1.18 | $-0.91 | $2.33 | $-1.10 | $-1.00 | $-1.24 | $-1.09 | $-1.17 |
| Shares Outstanding (M) | 104M | 103M | 105M | 103M | 102M | 88M | 83M | 82M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($359M) | ($345M) | ($347M) | ($149M) | $23M | ($66M) | ($96M) | ($72M) | ($20M) | ($3M) |
| Capital Expenditures (CapEx) | $13M | $15M | $9M | $34M | $49M | $47M | $16M | $13M | $13M | $0M |
| Free Cash Flow (FCF) | ($373M) | ($360M) | ($356M) | ($183M) | ($26M) | ($113M) | ($112M) | ($85M) | ($33M) | ($3M) |
| FCF Margin % | -238.9% | -257.6% | -560.8% | -48.4% | -43.4% | -218.1% | -467075.0% | -469561.1% | — | — |
| Dividends Paid | — | — | — | — | — | — | — | $13M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($66M) | ($129M) | ($83M) | ($81M) | ($76M) | ($104M) | ($76M) | ($88M) |
| Capital Expenditures (CapEx) | $2M | $2M | $4M | $5M | $3M | $3M | $3M | $2M |
| Free Cash Flow (FCF) | ($69M) | ($131M) | ($87M) | ($86M) | ($80M) | ($107M) | ($79M) | ($90M) |
| FCF Margin % | -13981.6% | -412.0% | -76.3% | -891.8% | -940.1% | -1431.7% | -263.9% | -628.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B | $1.5B | $1.1B | $1.5B | $1.3B | $1.5B | $452M | $156M | $167M | $2M |
| Cash & Cash Equivalents | $220M | $295M | $282M | $436M | $233M | $560M | $162M | $37M | $146M | $2M |
| Total Liabilities | $319M | $243M | $370M | $478M | $608M | $648M | $206M | $55M | $33M | $7M |
| Total Debt (Short + Long-Term) | $115M | $14M | $13M | $13M | $10M | $13M | $12M | $10M | $0M | $1M |
| Total Shareholders' Equity | $1.1B | $1.2B | $734M | $981M | $733M | $827M | $246M | $101M | $134M | ($4M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BEAM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms